ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0556

Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies

Edmund Chang1, Julian Low1, Noosha Yousefpour1, Min Bao1, Jeannette Osterloh1, Qing Chang1, Dean Artis1, Henk-Andre Kroon1, Yaisa Andrews-Zwilling1, Maria Dall'Era2, Ted Yednock1 and Ann Mongan1, 1Annexon Biosciences, Brisbane, CA, 2University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: complement, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease that can activate C1q and the classical complement pathway. Pathogenic anti-C1q antibodies (PACAs) are often present, amplifying classical pathway inflammation and contributing to progressive kidney damage. Elevated C4d and reduced C4 are markers of classical complement activation and consumption, respectively. For LN patients in the CLUES/UCSF Study, C4d/C4 ratio positively correlated with PACAs and urine protein-creatinine ratio (UPCR). To validate this correlation, the Sanguine Bio study was conducted.

Methods: Samples were collected from 40 LN patients (plus 20 healthy controls) from the CLUES/UCSF Study and 24 LN patients (plus 10 healthy controls) from Sanguine Bio. In the CLUES/UCSF Study, systemic lupus erythematosus (SLE) diagnoses were confirmed by study physicians according to either of the following definitions: (a) meeting ≥4 of the 11 ACR revised classification criteria for SLE as defined in 1982 and updated in 1997 or (b) meeting 3 of the 11 ACR criteria along with having SLE confirmed by a study rheumatologist. Complement activation and consumption (C4d, C4), exploratory biomarkers in plasma and urine, and UPCR were evaluated.

Results: Sanguine Bio samples from a subset of LN patients demonstrated elevated C4d/C4 compared to healthy controls, indicating classical complement pathway activation (Figure). Urinary biomarkers of LN correlated with C4d/C4 ratio in these patients.

Conclusion: In these LN patients, C4d/C4 ratios were elevated and correlated with LN biomarkers in blood and urine, supporting classical complement activity. These data support an ongoing, phase 1b study of ANX009 with the goal of assessing safety, tolerability, and pharmacodynamics of repeat doses of subcutaneous ANX009 with standard of care in adults with LN. ANX009 is an anti-C1q antigen binding fragment targeting LN patients with evidence of classical complement activity (elevated C4d/C4).

Supporting image 1

Figure. A Subset of Patients with LN Demonstrated Elevated C4d/C4 Over Healthy Controls


Disclosures: E. Chang: Annexon Biosciences, 3, 8; J. Low: Annexon Biosciences, 3, 8; N. Yousefpour: Annexon Biosciences, 3, 8; M. Bao: Annexon Biosciences, 3, 8, Roche/Genentech, 3, 8; J. Osterloh: Annexon Biosciences, 3, 8, FibroGen, Inc., 3; Q. Chang: Annexon Biosciences, 3, 8; D. Artis: Annexon Biosciences, 3, 8; H. Kroon: Annexon Biosciences, 3, 8; Y. Andrews-Zwilling: Annexon Biosciences, 3, 8; M. Dall'Era: Annexon Biosciences, 2, 5, AstraZeneca, 2, Aurinia, 2, Biogen, 2, GlaxoSmithKlein, 2, 5, Pfizer, 2; T. Yednock: Annexon Biosciences, 3, 8; A. Mongan: Annexon Biosciences, 3, 8.

To cite this abstract in AMA style:

Chang E, Low J, Yousefpour N, Bao M, Osterloh J, Chang Q, Artis D, Kroon H, Andrews-Zwilling Y, Dall'Era M, Yednock T, Mongan A. Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/classical-complement-activation-in-lupus-nephritis-correlates-with-disease-biomarkers-results-from-two-observational-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/classical-complement-activation-in-lupus-nephritis-correlates-with-disease-biomarkers-results-from-two-observational-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology